Umbilical cord blood transplantation (UCBT) has extended the availability of hematopoietic stem cell transplantation (HSCT) in the absence of a suitable donor and can be used in urgent situations such as graft failure. 1 Once considered a biological waste product, UCB has emerged as a viable source of HSCT. 2 UCB offers substantial clinical advantages such as 1) significantly faster availability of banked cryopreserved UCB units, with patients receiving UCBTs a median of 25 to 36 days earlier than those receiving bone marrow (BM); 2) expansion of the donor pool, because sufficiently large UCB units mismatched for 1 or 2 HLA-A, -B, and -DR antigens seem tolerated for survival; 3) a lower incidence and severity of acute graft-versus-host disease (GVHD); 4) a lower risk of transmitting infections by latent viruses, such as cytomegalovirus and Epstein-Barr virus, since the UCB is always tested for the presence of such viruses; 5) reduced donor attrition because cords can likely be stored longer than an average living donor remains available in a registry; and 6) easier targeting of ethnic minorities and an increased pool of rare haplotypes. 3 The major disadvantage of UCB units is the limited number of HSCs (using flow cytometry for identification and counting), as well as the collection that can occur only on a single occasion. In addition, compared with BM and peripheral blood (PB) transplantation, delayed hematopoietic reconstitution, higher risk of graft failure, and transplantation-related mortality occurs after therapeutic application of UCB cells. 4 Although there are numerous publications worldwide dealing with UCB cytometry parameters, such as CD34 + , 3 CD133 + , 5 and Mesenchymal cell concentration, 6 It is therefore the intent of this study to investigate the hematological profile of UCB.
Materials and Methods
UCB units (N=2000; 987 boys and 1,011 girls; P=0.607) were collected during labor by trained midwives and obstetricians with the placenta in utero immediately after clamping the cord and separating the infant between June 2008 and January 2009. All mothers and infants were in good general condition. In this study, an average UCB collection volume of 60.64 ± 25.47 mL without anticoagulant was obtained (mean ± SD; N=2,000). An informed consent document was signed from all the donors. All samples and solutions were processed After reading this article, readers should be able to evaluate umbilical cord blood hematological parameters. Some of these parameters are crucial for the further processing and isolation of the hematopoietic progenitor UCB cells, as well as the possibility of increased likelihood of rejection of a sample.
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Basophil The necessary equipment and instruments are shown in Table 1 . The collection bags (T2959; Fresenius Kabi AG, Bad Homburg, Germany; anticoagulant citrate phosphate dextrose 20 mL aggregate volume) were placed in a low position, which facilitates blood flow by gravity. 8 After collection and labeling of the bags with consecutive numbers and date and time of delivery, the samples were stored at room temperature and transported to the laboratory. Hematological analyses were performed using the automatic multiparameter hematology analyser A c •T 5diff (Beckman Coulter GmbH, Krefeld, Germany).
Results
All parameters were stable up to 72 hours and differential parameters were stable up to 48 hours. This result is of high value for centers that receive samples from outside collection points because such samples usually travel several hours prior to being tested. 9 Table 2_Umbilical The different norms for both genders are shown in Table  2 , in which the calculated ranges are in parallel with Beckman Coulter A c •T normal adult values as well as the European values. 10 The calculated hematological values were not statistically different among boys and girls, except for RDW, WBC, neutrophils, and PLT.
Discussion
The hematological profile of an individual to a large extent reflects his or her general health. 11 Since the assessment of hematological status is possible through a series of tests measuring different variables, it is valuable to have norms for the hematological indices. 12 Although profiles are generally available in the published literature as established norms, 13 there is no evidence that any studies were done to assess the applicability of these norms across populations and especially to the UCB. Subsequently, the proposed hematological ranges could be used as a guide for further UCB analyses. Using UCB with hematological values above or below the reference ranges could lead to an increased likelihood of rejection of the sample.
Hopefully, current research approaches and greater experience of transplant centers with UCBT will improve outcomes and will provide successful therapy to more patients who need a HSCT. 3 LM
